Pharmaceutical Business review

Taro granted approval for Ondansetron Injection

Taro’s Ondansetron Injection is used for the prevention of nausea and vomiting associated with chemotherapy. This new Taro sterile injectable prescription product is bioequivalent to GlaxoSmithKline’s Zofran Injection, 2mg/mL. Taro’s Ondansetron Injection will be manufactured in the company’s sterile facility in Ireland.